Department of Oncology, Hematology, BMT with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Janssen-Cilag AB, Solna, Sweden.
Eur J Haematol. 2022 Oct;109(4):388-397. doi: 10.1111/ejh.13821. Epub 2022 Jul 12.
This non-interventional observational study described the current standard-of-care for transplant-eligible newly diagnosed multiple myeloma (TE-NDMM) patients in France, Germany, Spain, and Italy, and recorded the evolution in regimen adoption in distinct elements of frontline treatment during 2017-2020/2021.
Clinical information on ongoing (I) or previous (II) TE-NDMM patients was extracted from the Cancerology database. Proportions of patients receiving regimens in each element and the evolution in regimen adoption were determined for the entire population and each country.
Most common induction regimens among I patients were VRd in France (75.3%) and Spain (44.1%), VTd in Italy (65.2%), and regimens other than VRd/VTd/VCd in Germany. Maintenance was ongoing/planned for 78.3%, 62.3%, 65.2%, and 61.4% patients in France, Germany, Spain, and Italy, respectively. Among II patients, VRd induction increased from 27.0% in 2017 to 65.7% in 2019 in France, remained relatively low in Spain and Germany, and not present in Italy. In Italy and Spain, VTd induction declined from 72.4% and 58.3% in 2017 to 52.8% and 17.3% in 2019, respectively. VCd induction in Germany declined from 85.2% in 2017 to 64.1% in 2019.
The use of bortezomib triplets in induction varied markedly over time and between selected countries.
本非干预性观察研究描述了法国、德国、西班牙和意大利符合移植条件的新诊断多发性骨髓瘤（TE-NDMM）患者的当前标准治疗，并记录了 2017-2020/2021 年一线治疗中不同治疗要素的方案采用演变情况。
从癌症学数据库中提取正在进行（I 期）或既往（II 期）TE-NDMM 患者的临床信息。确定每个要素中接受方案的患者比例以及方案采用的演变情况，包括整个患者群体和每个国家。
I 期患者中最常见的诱导方案是法国的 VRd（75.3%）和西班牙的 VRd（44.1%）、意大利的 VTd（65.2%）和德国的 VRd/VTd/VCd 以外的方案。78.3%、62.3%、65.2%和 61.4%的法国、德国、西班牙和意大利患者正在进行/计划进行维持治疗。在 II 期患者中，法国的 VRd 诱导从 2017 年的 27.0%增加到 2019 年的 65.7%，在西班牙和德国相对较低，在意大利则没有。在意大利和西班牙，VTd 诱导从 2017 年的 72.4%和 58.3%分别下降到 2019 年的 52.8%和 17.3%。德国的 VCd 诱导从 2017 年的 85.2%下降到 2019 年的 64.1%。
诱导治疗中硼替佐米三联药物的使用随时间和选定国家的不同而有很大差异。
